These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19404719)

  • 21. The interleukin 1B-511 polymorphism is associated with the risk of developing restenosis after coronary stenting in Mexican patients.
    Miranda-Malpica E; Martínez-Rios MA; Fragoso JM; Delgadillo-Rodríguez H; Rodríguez-Pérez JM; González-Quesada C; Martínez-Rodríguez N; Saldaña-Mendoza A; Peña-Duque MA; Vargas-Alarcón G
    Hum Immunol; 2008 Feb; 69(2):116-21. PubMed ID: 18361937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis -- comparison with stable and unstable angina.
    Kozinski M; Krzewina-Kowalska A; Kubica J; Zbikowska-Gotz M; Dymek G; Piasecki R; Sukiennik A; Grzesk G; Bogdan M; Chojnicki M; Dziedziczko A; Sypniewska G
    Inflamm Res; 2005 May; 54(5):187-93. PubMed ID: 15953990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
    de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
    Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiographic patterns of restenosis after percutaneous intervention of chronic total occlusive lesions with drug-eluting stents.
    Lee SP; Shin DH; Park KW; Kang HJ; Koo BK; Cho YS; Yeon TJ; Chae IH; Choi DJ; Kim HS
    Int J Cardiol; 2012 Apr; 156(2):180-5. PubMed ID: 21109317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of ACE gene polymorphisms with in-stent restenosis by stent type (biomime, supraflex, xience).
    Klashami ZN; Roudbordeh MG; Asadi M; Ebrahimi P; Amoli MM
    Mol Biol Rep; 2023 Aug; 50(8):6445-6455. PubMed ID: 37328581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relation of aortic stiffness and in-stent restenosis in patients undergoing percutaneous coronary stenting.
    Mahfouz RA; Abdulmoneim A; Abduo M; Elawady W
    Echocardiography; 2013 May; 30(5):582-7. PubMed ID: 23565733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting.
    Chiou KR; Chung SL; Charng MJ
    J Chin Med Assoc; 2005 Nov; 68(11):506-12. PubMed ID: 16323393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the extent of coronary artery disease and in-stent restenosis in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Yıldırım E; Çelik M; Yüksel UÇ; Buğan B; Gökoğlan Y; Görmel S; Yaşar S; Koklu M; İyisoy A; Barçın C
    Turk Kardiyol Dern Ars; 2017 Dec; 45(8):702-708. PubMed ID: 29226890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.
    Cheng G; Chang FJ; Wang Y; You PH; Chen HC; Han WQ; Wang JW; Zhong NE; Min ZQ
    Med Sci Monit; 2019 Jan; 25():240-247. PubMed ID: 30617247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ADA gene haplotype is associated with coronary-in-stent-restenosis.
    Gholami M; Borhan Dayani S; Mehrpooya M; Amoli MM
    Mol Biol Rep; 2021 Oct; 48(10):6665-6671. PubMed ID: 34510320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute coronary syndrome - a frequent clinical manifestation of bare metal in-stent restenosis.
    Drozd J; Wójcik J; Małek R; Korona B; Zapolski T; Wysokiński A
    Kardiol Pol; 2010 Jun; 68(6):637-45. PubMed ID: 20806192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balloon pin-hole rupture during percutaneous coronary intervention for recurrent, calcified in-stent restenosis: A case report.
    Murata N; Takayama T; Hiro T; Hirayama A
    Catheter Cardiovasc Interv; 2018 Jun; 91(7):1287-1290. PubMed ID: 29131504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.
    Kullmann S; Binner P; Rackebrandt K; Huge A; Haltern G; Lankisch M; Füth R; von Hodenberg E; Bestehorn HP; Scheffold T
    BMC Cardiovasc Disord; 2009 Oct; 9():48. PubMed ID: 19814804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis: the role of angiotensin converting enzyme inhibitors in stent restenosis in patients with diabetes mellitus.
    Guneri S; Baris N; Aytekin D; Akdeniz B; Pekel N; Bozdemir V
    Int Heart J; 2005 Sep; 46(5):889-97. PubMed ID: 16272779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do.
    Wang P; Qiao H; Wang R; Hou R; Guo J
    BMC Cardiovasc Disord; 2020 Dec; 20(1):510. PubMed ID: 33276720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of clinical outcomes of two different types of paclitaxel-coated balloons for treatment of patients with coronary in-stent restenosis.
    Nguyen VPT; Kim C; Hong SJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2019 Sep; 34(9):1420-1428. PubMed ID: 30903315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention.
    Beijk MA; Boekholdt SM; Rittersma SZ; Pons D; Zwinderman AH; Doevendans PA; Tio RA; Tijssen JG; Jukema JW; de Winter RJ
    Pharmacogenet Genomics; 2010 Sep; 20(9):544-52. PubMed ID: 20671584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.
    Habara S; Kadota K; Shimada T; Ohya M; Amano H; Izawa Y; Kubo S; Hyodo Y; Otsuru S; Hasegawa D; Tada T; Tanaka H; Fuku Y; Goto T; Mitsudo K
    J Am Coll Cardiol; 2015 Jul; 66(1):14-22. PubMed ID: 26139053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.